Yardley, PA, Oct. 17, 2017 — OptiNose, Inc. (NASDAQ:OPTN), a specialty pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the closing of its initial public offering of 8,625,000 shares of common stock at a public offering price of $16.00 per share, which includes an additional 1,125,000 shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares. The aggregate gross proceeds to Optinose from the offering were approximately $138 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Optinose. All of the shares were offered and sold by Optinose. The shares of common stock began trading on the NASDAQ Global Select Market on October 13, 2017 under the ticker symbol “OPTN.”
Jefferies and Piper Jaffray acted as the lead joint book-running managers of the offering. BMO Capital Markets and RBC Capital Markets also acted as joint book-running managers for the offering.
A registration statement relating to the securities sold in the offering was declared effective by the Securities and Exchange Commission on October 12, 2017. This offering was made only by means of a prospectus. Copies of the final prospectus relating to this offering were filed with the SEC and may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at 877-821-7388 or by email at Prospectus_Department@Jefferies.com; Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, or by telephone at 800-747-3924 or by email at email@example.com; BMO Capital Markets Corp., Attention: Equity Syndicate Department, 3 Times Square, 25th Floor, New York, NY 10036, or by telephone at 800-414-3627 or by email at firstname.lastname@example.org; and RBC Capital Markets LLC, Attention: Equity Syndicate, 200 Vesey Street, 8th Floor, New York, NY 10281-8098 or by telephone at 877-822-4089 or by email at email@example.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Optinose is a specialty pharmaceutical company on a mission to improve lives with a focus on patients cared for by ear, nose and throat (ENT) and allergy specialists. The Company’s first two products rely on our patented Exhalation Delivery Systems (EDS), which is capable of deep intranasal deposition of medication. These exhalation delivery systems enable the creation of products with the potential for meaningful new clinical benefits. Optinose developed its first product, Onzetra® Xsail® (sumatriptan nasal powder), through the completion of Phase 3 clinical trial and subsequently out-licensed the product to Otsuka Pharmaceutical Co., Ltd. Onzetra Xsail received FDA approval and was launched in the U.S. in 2016. The Company’s second product, XHANCE (fluticasone propionate) nasal spray, is approved for the treatment of nasal polyps in patients 18 years of age and older and is in development for the treatment of chronic sinusitis. We expect subsequent Optinose pipeline products will aim to serve the needs of patients treated by ENT and allergy specialists and are expected to develop those using EDS and other technologies. The Company is also currently engaged in the early development of products for neurologic orphan diseases where the “nose-to-brain” application of an EDS may enable improved treatment. This includes OPN-300 (Prader-Willi Syndrome, Autism, others) and OPN-21 (narcolepsy and others). Optinose has corporate offices in the U.S., U.K. and Norway.
Optinose Media Contact
Kate Traynor, Sloane & Company